$42.53
Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?
Overview
52-week range
$29
$61
42% of range
Avg surprise (last 3)
+68.0%
Avg reaction (last 2)
-0.3%
50% positive
Latest IV / EM
125%
EM ±19.6% · $45 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.31 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $0.37 | $0.23 | +60.9% | +105.6% | -1.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.24 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $0.31 | $0.19 | +63.2% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.18 | $0.10 | +80.0% | — | +0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.19 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.07 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.02 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.12 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.11 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $150M | $139M | — | $132M | $130M | $114M | — | $116M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $109M | $101M | — | $91M | $90M | $80M | — | $79M |
| Operating income | $23M | $23M | — | $23M | $-5M | $3M | — | $12M |
| Net income | $25M | $29M | — | $19M | $-980,000 | $7M | — | $15M |
| EPS (diluted) | $0.31 | $0.35 | — | $0.24 | $-0.01 | $0.09 | — | $0.19 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $300M | $263M | $363M | $316M | $219M | $186M | $239M | $274M |
| Inventory | — | — | — | $20M | $25M | $24M | $22M | $20M |
| Total current assets | $575M | $522M | $488M | $449M | $415M | $383M | $372M | $357M |
| Total assets | $1.49B | $1.44B | $1.41B | $1.37B | $1.34B | $1.32B | $1.30B | $1.28B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $98M | $92M | $96M | $110M | $123M | $120M | $124M | $99M |
| Total equity | $1.39B | $1.34B | $1.31B | $1.26B | $1.22B | $1.19B | $1.18B | $1.18B |